Texas to Tighten Ketamine Rules Amid Safety Debate

Texas is set to enact stringent new regulations on ketamine, a sedative increasingly used for mental health conditions. These rules, expected to be published on May 8 and voted on by the Texas Medical Board in June, mandate enhanced physician supervision during administration and prohibit in-home use.

The surge in ketamine's popularity for treating depression and PTSD has been accompanied by a rise in misuse and adverse effects. Data indicates ketamine poisonings more than doubled nationwide to 414 in 2023, with Texas seeing a rise in related poison center calls.

Under the proposed regulations, if a physician is not on-site, medical staff can only administer ketamine to two patients concurrently. Treatments must occur within registered clinics, and providers need mental health training. Supporters, like anesthesiologist Rep. Tom Oliverson, emphasize ketamine is a dangerous anesthetic, not a wellness treatment, requiring strict administration protocols.

Conversely, industry leaders and non-physician providers warn these regulations will severely restrict access and increase costs, potentially by $300 to $500 per treatment. They argue that advanced-practice registered nurses (APRNs) are capable of managing such treatments safely, comparing it to their roles in intensive care units. Critics label the rules a "power grab" by physicians aiming to "gut the industry."

Ketamine therapy, when paired with counseling in a clinical setting, is highly effective for severe mental illnesses. However, its potential for dependency and serious side effects like cardiovascular strain and respiratory depression with misuse is acknowledged. Providers stress that ketamine therapy requires significant client and provider effort, not just a "temporary fix."

Critics also point out that many ketamine clients are low-income and suicidal, for whom increased costs and limited access, particularly for rural patients relying on telehealth, could be devastating. The outcome of Texas's vote is seen as potentially influencing national regulations on this critical treatment.